Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2016 | Editorial Commentary

The promise of multiparametric imaging in oncology: how do we move forward?

Authors: Aniek J. G. Even, Dirk De Ruysscher, Wouter van Elmpt

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2016

Excerpt

With the introduction of combined imaging modalities including PET/CT and more recently PET/MRI, there is strong interest in utilizing these independent modalities in a synergistic way. Up to now the field of multiparametric imaging research has mainly been driven by the MRI community. MRI offers the possibility of acquiring different sequences to visualize diverse properties of tissues (e.g. ADC mapping, T1/T2-weighted images). In the recent issues of EJNMMI there are several research papers looking into the topic of multiparametric imaging in a variety of cancer types using combined nuclear medicine imaging techniques with a different number of tracers together with advanced MR or CT imaging equipment [1‐5]. Besides MRI, other drivers beneficial for multiparametric imaging are the increased number of standardization procedures that are being rolled out. For PET [6] and also MRI [7], standardization (or harmonization) procedures are currently in place or being developed. These procedures should remove some of the uncertainties and difficulties that multicentre trials face in quantitative analysis and allow more robust quantitative imaging-derived parameters [8]. …

Leibfarth S, Simoncic U, Monnich D, Welz S, Schmidt H, Schwenzer N, et al. Analysis of pairwise correlations in multi-parametric PET/MR data for biological tumor characterization and treatment individualization strategies. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3307-7.PubMed

Sauter AW, Schwenzer N, Divine MR, Pichler BJ, Pfannenberg C. Image-derived biomarkers and multimodal imaging strategies for lung cancer management. Eur J Nucl Med Mol Imaging. 2015;42:634–43. doi:10.1007/s00259-014-2974-5.CrossRefPubMed

Corroyer-Dulmont A, Peres EA, Gerault AN, Savina A, Bouquet F, Divoux D, et al. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2016;43:682–94. doi:10.1007/s00259-015-3225-0.CrossRefPubMed

Henriksen OM, Larsen VA, Muhic A, Hansen AE, Larsson HB, Poulsen HS, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43:103–12. doi:10.1007/s00259-015-3183-6.CrossRefPubMed

van Elmpt W, Zegers CM, Reymen B, Even AJ, Dingemans AM, Oellers M, et al. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging. 2016;43:240–8. doi:10.1007/s00259-015-3169-4.CrossRefPubMedPubMedCentral

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. doi:10.1007/s00259-014-2961-x.CrossRefPubMedPubMedCentral

Gatidis S, Schmidt H, Martirosian P, Schwenzer NF. Development of an MRI phantom for diffusion-weighted imaging with independent adjustment of apparent diffusion coefficient values and T2 relaxation times. Magn Reson Med. 2014;72:459–63. doi:10.1002/mrm.24944.CrossRefPubMed

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, et al. Quantitative imaging in cancer clinical trials. Clin Cancer Res. 2016;22:284–90. doi:10.1158/1078-0432.CCR-14-3336.CrossRefPubMed

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v31–9. doi:10.1093/annonc/mdv199.CrossRefPubMed

10.

Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. doi:10.1093/annonc/mdv222.CrossRefPubMed

11.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, et al. Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185–90. doi:10.2967/jnumed.115.160382.CrossRefPubMed

12.

Iqbal R, Kramer GM, Verwer EE, Huisman MC, De Langen AJ, Bahce I, et al. Multiparametric analysis of the relationship between tumor hypoxia and perfusion using 18F-FAZA and 15O-H2O PET. J Nucl Med. 2015. doi:10.2967/jnumed.115.166579.PubMed

13.

Bradshaw TJ, Bowen SR, Jallow N, Forrest LJ, Jeraj R. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors. J Nucl Med. 2013;54:1931–7. doi:10.2967/jnumed.113.121921.CrossRefPubMedPubMedCentral

14.

Metz S, Ganter C, Lorenzen S, van Marwick S, Holzapfel K, Herrmann K, et al. Multiparametric MR and PET imaging of intratumoral biological heterogeneity in patients with metastatic lung cancer using voxel-by-voxel analysis. PLoS One. 2015;10:e0132386. doi:10.1371/journal.pone.0132386.CrossRefPubMedPubMedCentral

15.

Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–92. doi:10.1016/j.radonc.2009.03.006.CrossRefPubMedPubMedCentral

16.

Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol. 2014;111:360–5. doi:10.1016/j.radonc.2014.06.001.CrossRefPubMedPubMedCentral

17.

Zschaeck S, Haase R, Abolmaali N, Perrin R, Stutzer K, Appold S, et al. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. Acta Oncol. 2015;54:1355–63. doi:10.3109/0284186X.2015.1074720.CrossRefPubMed

18.

Weber DC, Casanova N, Zilli T, Buchegger F, Rouzaud M, Nouet P, et al. Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol. 2009;93:586–92. doi:10.1016/j.radonc.2009.08.043.CrossRefPubMed

19.

Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4:822–8. doi:10.1097/JTO.0b013e3181a97df7.CrossRefPubMed

20.

van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer. 2007;43:1392–8. doi:10.1016/j.ejca.2007.03.027.CrossRefPubMed

21.

Mazaheri Y, Hricak H, Fine SW, Akin O, Shukla-Dave A, Ishill NM, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology. 2009;252:449–57. doi:10.1148/radiol.2523081423.CrossRefPubMedPubMedCentral

22.

Puri T, Chalkidou A, Henley-Smith R, Roy A, Barber PR, Guerrero-Urbano T, et al. A method for accurate spatial registration of PET images and histopathology slices. EJNMMI Res. 2015;5:64. doi:10.1186/s13550-015-0138-7.CrossRefPubMedPubMedCentral

23.

Christian N, Lee JA, Bol A, De Bast M, Jordan B, Gregoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol. 2009;91:101–6. doi:10.1016/j.radonc.2008.11.014.CrossRefPubMed

24.

Berwouts D, Olteanu LA, Duprez F, Vercauteren T, De Gersem W, De Neve W, et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. Radiother Oncol. 2013;107:310–6. doi:10.1016/j.radonc.2013.04.002.CrossRefPubMed

25.

Differding S, Hanin FX, Gregoire V. PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging. 2015;42:613–22. doi:10.1007/s00259-014-2972-7.CrossRefPubMed

26.

van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomized phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol. 2012;104:67–71. doi:10.1016/j.radonc.2012.03.005.CrossRefPubMed

27.

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346:251–6. doi:10.1126/science.1253462.CrossRefPubMedPubMedCentral

28.

Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol. 2015;33:3701–9. doi:10.1200/JCO.2014.58.8293.CrossRefPubMedPubMedCentral

29.

Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, et al. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Clin Cancer Res. 2013;19:183–93. doi:10.1158/1078-0432.CCR-12-0289.CrossRefPubMed

30.

Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin Cancer Res. 2015;21:2984–92. doi:10.1158/1078-0432.CCR-15-0018.CrossRefPubMed

Title: The promise of multiparametric imaging in oncology: how do we move forward?
Authors: Aniek J. G. Even
Dirk De Ruysscher
Wouter van Elmpt
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3361-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The promise of multiparametric imaging in oncology: how do we move forward?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2016

Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18F-DPA-714 and micro-PET/CT

Dual-phase amyloid PET: hitting two birds with one stone

Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls

Erratum to: EANM '15 Annual Congress of the European Association of Nuclear Medicine, October 10–14, 2015, Hamburg, Germany

Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment

Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease